JP2015520221A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520221A5
JP2015520221A5 JP2015517850A JP2015517850A JP2015520221A5 JP 2015520221 A5 JP2015520221 A5 JP 2015520221A5 JP 2015517850 A JP2015517850 A JP 2015517850A JP 2015517850 A JP2015517850 A JP 2015517850A JP 2015520221 A5 JP2015520221 A5 JP 2015520221A5
Authority
JP
Japan
Prior art keywords
disease
dementia
alzheimer
treating
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015517850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520221A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2013/051606 external-priority patent/WO2013190302A1/en
Publication of JP2015520221A publication Critical patent/JP2015520221A/ja
Publication of JP2015520221A5 publication Critical patent/JP2015520221A5/ja
Pending legal-status Critical Current

Links

JP2015517850A 2012-06-21 2013-06-20 カンシル酸塩 Pending JP2015520221A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662592P 2012-06-21 2012-06-21
US61/662,592 2012-06-21
PCT/GB2013/051606 WO2013190302A1 (en) 2012-06-21 2013-06-20 Camsylate salt

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018021595A Division JP6509393B2 (ja) 2012-06-21 2018-02-09 カンシル酸塩

Publications (2)

Publication Number Publication Date
JP2015520221A JP2015520221A (ja) 2015-07-16
JP2015520221A5 true JP2015520221A5 (enExample) 2016-08-12

Family

ID=48746084

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015517850A Pending JP2015520221A (ja) 2012-06-21 2013-06-20 カンシル酸塩
JP2018021595A Active JP6509393B2 (ja) 2012-06-21 2018-02-09 カンシル酸塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018021595A Active JP6509393B2 (ja) 2012-06-21 2018-02-09 カンシル酸塩

Country Status (42)

Country Link
US (1) US10548882B2 (enExample)
EP (2) EP2864316B1 (enExample)
JP (2) JP2015520221A (enExample)
KR (1) KR102123708B1 (enExample)
CN (2) CN106279102A (enExample)
AP (2) AP2017009693A0 (enExample)
AR (2) AR091495A1 (enExample)
AU (2) AU2013279109B2 (enExample)
BR (2) BR112014031531B1 (enExample)
CA (1) CA2875589C (enExample)
CL (1) CL2014003374A1 (enExample)
CO (1) CO7151486A2 (enExample)
CR (2) CR20140571A (enExample)
CY (1) CY1119505T1 (enExample)
DK (1) DK2864316T3 (enExample)
DO (1) DOP2014000268A (enExample)
EC (1) ECSP14032215A (enExample)
ES (1) ES2618939T3 (enExample)
HR (1) HRP20170359T1 (enExample)
HU (1) HUE033376T2 (enExample)
IL (1) IL236131A0 (enExample)
IN (1) IN2014DN10088A (enExample)
LT (1) LT2864316T (enExample)
MA (2) MA39259B1 (enExample)
ME (1) ME02633B (enExample)
MX (1) MX354214B (enExample)
NI (1) NI201400146A (enExample)
NZ (2) NZ702742A (enExample)
PE (1) PE20150670A1 (enExample)
PH (2) PH12014502803A1 (enExample)
PL (1) PL2864316T3 (enExample)
PT (1) PT2864316T (enExample)
RS (1) RS55815B1 (enExample)
RU (1) RU2638175C2 (enExample)
SG (1) SG11201407934UA (enExample)
SI (1) SI2864316T1 (enExample)
SM (1) SMT201700142T1 (enExample)
TN (1) TN2014000491A1 (enExample)
TW (2) TWI588140B (enExample)
UA (1) UA114196C2 (enExample)
WO (1) WO2013190302A1 (enExample)
ZA (1) ZA201500408B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
WO2013054108A1 (en) 2011-10-10 2013-04-18 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
AR102202A1 (es) 2014-10-07 2017-02-08 Astrazeneca Ab Compuestos de oxazol y su uso como inhibidores de bace de oxazol
JP6546410B2 (ja) * 2015-02-23 2019-07-17 ローム株式会社 電力供給装置、acアダプタ、acチャージャ、電子機器および電力供給システム
WO2017158064A1 (en) 2016-03-15 2017-09-21 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
TW201740944A (zh) 2016-03-15 2017-12-01 美國禮來大藥廠 組合療法
AU2020234033B2 (en) * 2019-03-14 2023-07-13 Astrazeneca Ab Lanabecestat for weight loss

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
WO2002098462A1 (en) 2001-06-01 2002-12-12 Ono Pharmaceutical Co., Ltd. Remedies containing aldose reductase inhibitor as the active ingredient for demyelinating diseases or diseases associated with demyelination
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2005094822A1 (en) 2004-03-22 2005-10-13 Eli Lilly And Company Pyridyl derivatives and their use as mglu5 receptor antagonists
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
WO2007058601A1 (en) 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
US20080318929A1 (en) 2005-12-21 2008-12-25 Barbosa Antonio J M Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
EP2644600B1 (en) 2006-06-12 2017-01-11 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
WO2008076043A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
EP2108018A2 (en) 2007-02-01 2009-10-14 Glaxo Group Limited 8-oxa-1,4-diazaspiro [4,5] dec-3-en-1-yl and 1,4,8-triazaspiro [4,5] dec-3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
WO2008137139A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
EP2249646A4 (en) 2008-02-06 2013-09-25 Glaxo Group Ltd PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
FR2929943B1 (fr) * 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
ES2433223T3 (es) 2008-07-28 2013-12-10 Eisai R&D Management Co., Ltd. Derivados de espiroaminodihidrotiazina
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
MX2011002705A (es) 2008-09-11 2011-09-09 Amgen Inc Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
ES2571057T3 (es) 2009-03-13 2016-05-23 Vitae Pharmaceuticals Inc Inhibidores de beta-secretasa
TW201105650A (en) 2009-07-02 2011-02-16 Astrazeneca Ab New compounds
AR077365A1 (es) 2009-07-02 2011-08-24 Astrazeneca Ab Derivados de imidazol para el tratamiento de enfermedades mediadas por la inhibicion de la formacion de abeta
CN102812005B (zh) 2010-02-24 2014-12-10 生命医药公司 β-分泌酶抑制剂
US20120065195A1 (en) 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
US20120083501A1 (en) 2010-09-24 2012-04-05 Hunt Kevin W Compounds for treating neurodegenerative diseases
AR083953A1 (es) 2010-11-22 2013-04-10 Array Biopharma Inc Compuestos para tratar enfermedades neurodegenerativas
US8415483B2 (en) * 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
WO2013054108A1 (en) 2011-10-10 2013-04-18 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors

Similar Documents

Publication Publication Date Title
JP2015520221A5 (enExample)
RU2014148305A (ru) Камсилатная соль
ME02728B (me) Jedinjenja i njihova upotreba kao bace inhibitori
JP2015500223A5 (enExample)
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2011504474A5 (enExample)
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2019524822A5 (enExample)
BR112014029016A2 (pt) derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012080729A3 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
NZ630589A (en) Methods of treating alzheimer’s disease and pharmaceutical compositions thereof
IL278188B2 (en) Sublingual formulation of riluzole
PH12021551541A1 (en) Compositions and methods for treating neurodegenerative disorders
JP2016512817A5 (enExample)
HK1206350A1 (en) 2h-imidazol-4-amine compounds and their use as bace inhibitors
WO2012091593A8 (en) Granulates comprising eslicarbazepine acetate
JP2019516756A5 (enExample)
HK1206348A1 (en) Cyclohexane-1,2'-indene-1',2"-imidazol compounds and their use as bace inhibitors
JP2015500300A5 (enExample)
JP2013537901A5 (enExample)
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
JOP20190180A1 (ar) مشتق أوكسازين حر القاعدة في صورة بلورية
WO2015166418A3 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol